- Oops!Something went wrong.Please try again later.
Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson’s (NYSE: JNJ) single-dose COVID-19 vaccine.
Under the contract, the capacity at IDT’s Dessau site, previously reserved to make Takeda’s dengue vaccine candidate, will be used to make J&J’s COVID-19 vaccine for worldwide distribution.
After three months, the capacity will be returned to Takeda to resume manufacturing for its dengue vaccine’s planned launch.
Price Action: TAK shares are trading 2.25% higher at 18.85, and JNJ shares are up 0.41% at $160.25 in market trading hours on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.